TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 9.890

+3.1%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (538)	5/30/2008 2:26:44 PM
From: Mike McFarland	Read Replies (1) of 557

TGEN announced additional interim data from its Phase 1/2 clinical study of tgAAC94 in patients with inflammatory arthritis ir.targen.com (snip) Although these results do not provide statistical evidence of efficacy, we believe they suggest that tgAAC94 has the potential to improve disease symptoms that are refractory to other therapies, including systemic TNF antagonists," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "These clinical observations will help guide further clinical development. Additional treatment options are essential for allowing all patients with inflammatory arthritis to achieve optimal relief of their symptoms.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next